SCHEMBL430259

SCHEMBL430259

NC(=O)C1CCc2ccccc2O1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC2 Q92769 1/20 0.49
CA2 P00918 2/20 0.47
HSD11B1 P28845 1/20 0.45
HPGD P15428 2/20 0.45
TSHR P16473 1/20 0.45
NISCH Q9Y2I1 1/20 0.44
SIRT1 Q96EB6 2/20 0.43
SIRT2 Q8IXJ6 1/20 0.43
CYP2D6 P10635 2/20 0.42
OPRK1 P41145 2/20 0.42
AOC2 O75106 5/20 0.42
MAOA P21397 5/20 0.42
MAOB P27338 5/20 0.42
DAO P14920 1/20 0.42
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5695491 1.00 HDAC3 (0.49) HDAC3HDAC1HDAC2CA2HSD11B1
SCHEMBL30887999 1.00 HDAC3 (0.49) HDAC3HDAC1HDAC2CA2HSD11B1
SCHEMBL4934593 1.00 HDAC3 (0.49) HDAC3HDAC1HDAC2CA2HSD11B1
SCHEMBL27274507 0.92 HDAC3 (0.45) HDAC3HDAC1HDAC2CA2HSD11B1
SCHEMBL5847076 0.90 HPGD (0.47) HDAC3HDAC1HDAC2CA2HPGD
SCHEMBL30525289 0.87 HDAC3 (0.47) HDAC3HDAC1HDAC2CA2HSD11B1
Benzenesulfonamide SCHEMBL4672289 0.87 CA2 (0.47) HDAC3HDAC1HDAC2CA2HSD11B1
SCHEMBL229558 0.86 HPGD (0.49) HDAC3HDAC1HDAC2CA2HSD11B1
SCHEMBL1567147 0.86 HDAC3 (0.46) HDAC3HDAC1HDAC2CA2HSD11B1
SCHEMBL2286036 0.86 HPGD (0.49) HDAC3HDAC1HDAC2CA2HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024153595-A1 CHROMANE DERIVATIVES AS EGFR SELECTIVE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2024-07-25 WO claimed
US-9743665-B2 Fungicidal 3-{phenyl[heterocyclylmethoxy)imino]methyl}-oxadiazolone derivatives BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2017-08-29 US claimed
EP-1673362-A2 METHOD FOR PRODUCING CHROMANE DERIVATIVES THAT ARE DEVOID OF ENANTIOMERS AND ARE SUBSTITUTED IN POSITION 2 MERCK PATENT GmbH (DE) 2006-06-28 EP claimed
WO-2005037817-A2 METHOD FOR PRODUCING CHROMANE DERIVATIVES THAT ARE DEVOID OF ENANTIOMERS AND ARE SUBSTITUTED IN POSITION 2 MERCK PATENT GMBH (DE) 2005-04-28 WO claimed
EP-0231139-B1 DIHYDROBENZOFURANE AND CHROMANE CARBOXAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS NEUROLEPTICS Laboratoires DELAGRANGE (FR) 1991-12-04 EP claimed
US-5006570-A Dihydrobenzofuran- and chroman-carboxamide derivatives, processes for the preparation thereof and use thereof as neuroleptics LABORATOIRES DELAGRANGE (FR) 1991-04-09 US claimed
CN-87100978-A Dihydrobenzofuran-and chroman-carboxamide derivatives, processes for their preparation and their use as neuroleptics 1987-09-16 CN claimed
EP-0115142-B1 CHROMAN COMPOUNDS ICI AMERICAS INC. (US) 1986-11-05 EP claimed
EP-0115142-A1 Chroman compounds ICI AMERICAS INC. (US) 1984-08-08 EP claimed
US-20250145594-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2025-05-08 US disclosed
WO-2024153595-A1 CHROMANE DERIVATIVES AS EGFR SELECTIVE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2024-07-25 WO disclosed
EP-3505513-B1 ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS IND TECH RES INST (TW) 2023-09-27 EP disclosed
EP-4237413-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2023-09-06 EP disclosed
EP-3676297-B1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC (US) 2023-05-17 EP disclosed
CN-1039809-A The aminomethyl tetraline that replaces and the preparation of heterocycle homologue thereof BAYER AG (DE) 1990-02-21 CN disclosed
CN-87100978-A Dihydrobenzofuran-and chroman-carboxamide derivatives, processes for their preparation and their use as neuroleptics 1987-09-16 CN disclosed
EP-0231139-A2 Dihydrobenzofurane and chromane carboxamide derivatives, processes for their preparation and their use as neuroleptics Laboratoires DELAGRANGE (FR) 1987-08-05 EP disclosed
EP-0231139-A2 Dihydrobenzofurane and chromane carboxamide derivatives, processes for their preparation and their use as neuroleptics Laboratoires DELAGRANGE (FR) 1987-08-05 EP disclosed
EP-0115142-B1 CHROMAN COMPOUNDS ICI AMERICAS INC. (US) 1986-11-05 EP disclosed
EP-0115142-A1 Chroman compounds ICI AMERICAS INC. (US) 1984-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145594-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 HDAC3 359/4885HDAC1 309/4885HDAC2 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.